Indian pharma major making branded generics, APIs, biosimilars and medical devices, sold across 40+ countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 6.1k | 7.4k | 8.6k | 9.0k | 10.3k | 12.0k | 13.3k | 13.8k |
| Borrowings | 1.6k | 1.7k | 2.7k | 1.4k | 1.4k | 1.4k | 2.4k | 2.0k |
| Other Liabilities | 2.2k | 2.4k | 2.8k | 3.3k | 3.8k | 4.3k | 4.6k | 5.0k |
| Total Liabilities | 9.9k | 11.5k | 14.1k | 13.8k | 15.6k | 17.7k | 20.3k | 20.9k |
| AssetsFixed Assets | 2.9k | 2.8k | 2.9k | 2.7k | 2.9k | 2.9k | 3.3k | 4.0k |
| CWIP | 363 | 393 | 339 | 323 | 159 | 548 | 653 | 138 |
| Investments | 261 | 333 | 371 | 622 | 484 | 1.8k | 2.5k | 1.9k |
| Other Assets | 6.4k | 8.0k | 10.5k | 10.1k | 12.1k | 12.4k | 13.8k | 14.9k |
| Total Assets | 9.9k | 11.5k | 14.1k | 13.8k | 15.6k | 17.7k | 20.3k | 20.9k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 780 | 585 | 1.3k | 1.1k | 1.7k | 1.9k | 1.9k | 2.0k |
| Cash from Investing | -318 | -737 | -995 | -1.4k | 120 | -1.0k | -1.3k | -1.7k |
| Cash from Financing | -379 | 79 | -272 | 380 | -1.8k | -1.1k | -811 | -503 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 253 | 237 | 1.1k | 783 | 1.5k | 1.8k | 1.3k | 1.5k |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (30.1×) and current (27.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 32.7% growth and a 28× exit, ₹5374 only delivers your return if you pay ₹10,550. The price is currently baking in 17% growth.
EPS grows 32.7%/yr for 5 years, then fades to 6% over 2, exits at 28×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 32.7% | 255.47 |
| FY28 | 32.7% | 339.01 |
| FY29 | 32.7% | 449.87 |
| FY30 | 32.7% | 596.98 |
| FY31 | 32.7% | 792.19 |
| FY32 | 19.4% ·fade | 945.48 |
| FY33 | 6.0% ·fade | 1002.21 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.